We couldn't find that disease.
Can a simple test predict who will respond to this sarcoma drug?
NCT ID NCT04008238
First seen Nov 01, 2025
Summary
This study aims to find biological markers that can predict whether the drug trabectedin will work in patients with certain types of soft-tissue sarcoma. Researchers will collect tumor biopsies and blood samples from 29 participants before and during treatment. The goal is to use advanced testing to identify which patients are most likely to benefit, potentially leading to more personalized treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIOID SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institut Bergonie
Bordeaux, 33076, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trabectedin
What this could lead to
If successful, this could help doctors identify which sarcoma patients are most likely to benefit from trabectedin, making treatment more personalized.
What could go wrong
This is a small, early-stage study focused on finding biomarkers, not on proving treatment effectiveness. The results may not apply to all sarcoma types or lead to immediate changes in care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.